^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Empliciti (elotuzumab)

    i
    Other names: BMS-901608, HuLuc63, PDL063, BMS901608, BMS 901608, HuLuc-63, PDL 036, PDL-063
    Company:
    AbbVie, BMS
    Drug class:
    CS-1 inhibitor
    Related drugs:
    22d
    SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma. (PubMed, Cancers (Basel))
    The target has a proven clinical success with Elotuzumab (anti-SLAMF7 antibody); it works by activating immune cells to kill myeloma cells, and limited expression on normal tissues, with, potentially, few side effects...However, 'fratricide death', a phenomenon where the engineered CAR-T cells attack and kill each other, is a critical issue that requires safe engineering solutions. In this work, we will provide an overview on the field with a specific focus on SLAMF7 as an emerging CAR-T cell target in MM.
    Review • Journal • IO biomarker
    |
    SLAMF7 (SLAM Family Member 7)
    |
    Empliciti (elotuzumab)
    2ms
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2027 --> Jan 2028
    Trial completion date
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    2ms
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2030 --> Jun 2027
    Trial completion date
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    3ms
    Elo-KRd: Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, University of Chicago | Trial completion date: Mar 2029 --> Mar 2027
    Trial completion date
    |
    lenalidomide • carfilzomib • Empliciti (elotuzumab)
    3ms
    A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    bortezomib • pomalidomide • Empliciti (elotuzumab)
    4ms
    CA204-219: A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan (clinicaltrials.gov)
    P=N/A, N=7, Completed, Bristol-Myers Squibb | Recruiting --> Completed | N=27 --> 7 | Trial completion date: Dec 2026 --> Mar 2025 | Trial primary completion date: Jun 2025 --> Mar 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    lenalidomide • pomalidomide • Empliciti (elotuzumab)
    6ms
    Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series. (PubMed, Hematology)
    None of the patients died during the median follow-up period of 39 months (range, 3-66 months). Daratumumab- and elotuzumab-based regimens may be treatment options for refractory POEMS syndrome.
    Retrospective data • Journal
    |
    SLAMF7 (SLAM Family Member 7)
    |
    Darzalex (daratumumab) • Empliciti (elotuzumab)
    6ms
    SWOG-1211: S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=142, Active, not recruiting, SWOG Cancer Research Network | Trial completion date: Mar 2025 --> Dec 2025
    Trial completion date
    |
    SKY92 Test
    |
    lenalidomide • bortezomib • Empliciti (elotuzumab) • dexamethasone injection
    6ms
    CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Dec 2024 --> Nov 2025 | Trial primary completion date: Dec 2024 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab)
    7ms
    Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=113, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2025 --> Apr 2027 | Trial primary completion date: Apr 2025 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Empliciti (elotuzumab)
    8ms
    AlloRelapseMM: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (clinicaltrials.gov)
    P3, N=28, Terminated, Universitätsklinikum Hamburg-Eppendorf | N=482 --> 28 | Trial completion date: Mar 2033 --> Mar 2025 | Recruiting --> Terminated | Trial primary completion date: Mar 2028 --> Mar 2025; The reason for the end of recruitment is that the recruitment target could not be achieved despite all efforts and the G-BA (financing party) does not consider a continuation of the AlloRelapseMM study to be expedient.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    lenalidomide • bortezomib • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • carfilzomib • pomalidomide • Sarclisa (isatuximab-irfc) • Empliciti (elotuzumab)
    8ms
    Elo-KRd: LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=15, Completed, Wake Forest University Health Sciences | Active, not recruiting --> Completed
    Trial completion
    |
    lenalidomide • carfilzomib • Empliciti (elotuzumab)